Advertisement
Advertisement
ARVN
Arvinas, Inc
8.75
USDSponsored
+0.07
+0.81%
Aug 07, 15:59 UTC -4
Closed
After-Market
8.61
-0.14
-1.60%
ARVN Earnings Reports
Positive Surprise Ratio
ARVN beat 16 of 32 last estimates.
50%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$28.75M
/-$0.78
Implied change from Q2 26 (Revenue/ EPS)
-88.49%
/-130.23%
Implied change from Q3 25 (Revenue/ EPS)
-31.39%
/+62.50%
Arvinas, Inc earnings per share and revenue
On Aug 04, 2026, ARVN reported earnings of 2.58 USD per share (EPS) for Q2 26, beating the estimate of -0.37 USD, resulting in a 783.99% surprise. Revenue reached 249.70 million, compared to an expected 33.19 million, with a 652.27% difference. The market reacted with a +11.66% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.78 USD, with revenue projected to reach 28.75 million USD, implying an decrease of -130.23% EPS, and decrease of -88.49% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
FAQ
What were Arvinas, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Arvinas, Inc reported EPS of $2.58, beating estimates by 783.99%, and revenue of $249.70M, 652.27% above expectations.
How did the market react to Arvinas, Inc's Q2 2026 earnings?
The stock price moved up 11.66%, changed from $8.06 before the earnings release to $9.00 the day after.
When is Arvinas, Inc expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Arvinas, Inc's next earnings report?
Based on 12
analysts, Arvinas, Inc is expected to report EPS of -$0.78 and revenue of $28.75M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement